Not all NOACs are created equal

It is well-known that all new oral anticoagulants increase the risk for gastrointestinal bleeding (GIB), but new research shows some are more problematic than others.

Gastrointestinal bleeding (GIB) risks are lower with apixaban than with dabigatran or rivaroxaban,the results show.